Cf-DNA Assay During Treatment of Acute Rejection

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions
Kidney Transplant Failure and RejectionKidney Transplant; ComplicationsKidney Transplant RejectionTransplant; Complication, RejectionTransplant Dysfunction
Interventions
GENETIC

cf-DNA Collection

"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection | Biotech Hunter | Biotech Hunter